Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication

David T. Wong, Frank P. Bymaster, Eric A. Engleman

Research output: Contribution to journalShort survey

517 Scopus citations

Abstract

In this review, we describe the evolutionary process involved in the discovery of the selective 5-HT uptake inhibitor, fluoxetine, and summarize some of the large body of scientific research performed on fluoxetine in the 20 years since the first publication. The historical background of the proposed involvement of 5-HT in psychiatric disorders and the activity of tricyclic antidepressants in depression is reviewed. The effects of fluoxetine in various in vitro assays and in animal studies including receptor down-regulation, neurochemical and behavioral models are summarized. In addition, the clinical effectiveness of fluoxetine in depression and obsessive compulsive disorders and its potential use in other disorders are examined.

Original languageEnglish (US)
Pages (from-to)411-441
Number of pages31
JournalLife Sciences
Volume57
Issue number5
DOIs
StatePublished - Jun 23 1995
Externally publishedYes

Keywords

  • Prozac
  • antidepressant
  • fluoxetine
  • inhibitor
  • serotonin
  • uptake

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication'. Together they form a unique fingerprint.

Cite this